Y disruption, autosomal hypomethylation and poor male lung cancer survival

…, L Liang, MB Freidin, M Arseneault, Y Zhang, SK Lu… - Scientific Reports, 2021 - nature.com
Lung cancer is the most frequent cause of cancer death worldwide. It affects more men than
women, and men generally have worse survival outcomes. We compared gene co-…

Integrated genomics point to immune vulnerabilities in pleural mesothelioma

A Nastase, A Mandal, SK Lu, H Anbunathan… - Scientific Reports, 2021 - nature.com
Pleural mesothelioma is an aggressive malignancy with limited effective therapies. In order
to identify therapeutic targets, we integrated SNP genotyping, sequencing and …

[HTML][HTML] KRAS mutation: characterization and its impact on survival outcome of patients with metastatic colorectal cancer

…, LL Chaw, SK Lu, PU Telisinghe, ZH Lu… - Frontiers in Bioscience …, 2022 - imrpress.com
Introduction: Colorectal cancer (CRC) is one of the most common cancer types, with rising
incidence due to imbalanced lifestyle and dietary habit. Association between CRC cases and …

Incidence, survival and prognostic factors of oesophagogastric cancer

NS Ishak, H Abdul Rahman, SHF Lee, SK Lu… - Journal of …, 2022 - Springer
Introduction Oesophagogastric cancer is one of the leading causes of cancer death worldwide
due to its aggressive nature. Despite the high mortality rate, there is limited information …

A pilot study of a novel home telemonitoring system for oncology patients receiving chemotherapy

K Nimako, SK Lu, B Ayite, K Priest… - … of telemedicine and …, 2013 - journals.sagepub.com
We examined the accuracy and acceptability of a home telemonitoring system for patients
receiving chemotherapy. Patients undergoing two cycles of chemotherapy (over six weeks) …

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients

R Kumar, SK Lu, A Minchom, A Sharp… - Cancer chemotherapy …, 2016 - Springer
Purpose Erlotinib is active in advanced non-small cell lung cancer (aNSCLC) particularly in
patients with EGFR-sensitizing mutations. The thymidylate synthase inhibitors are active in …

Survival Analysis of Diabetic Colorectal Cancer Patients on Metformin

AB Wong, R Patnaik, LL Chaw, SK Lu… - Progress In Microbes …, 2023 - hh-publisher.com
Metformin, an antihyperglycemic drug, has been associated with antineoplastic effects and
could potentially improve colorectal cancer prognosis. The association between metformin …

Survival Analysis of Diabetic Colorectal Cancer Patients On Metformin in Brunei Darussalam

AB Wong, R Patnaik, LL Chaw, SK Lu, YC Lim - 2023 - researchsquare.com
Metformin, an antihyperglycemic drug, has been associated with antineoplastic effects and
could potentially improve colorectal cancer prognosis. There are several conflicting data with …

EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AND PROGNOSIS IN NON-SMALL CELL LUNG CANCER CASES IN BRUNEI DARUSSALAM.

…, L NAING, PU TELISINGHE, SK LU - Brunei International …, 2019 - search.ebscohost.com
Introduction: This study characterizes Epidermal Grow th Factor Receptor (EGFR) mutations
in patients with non-small cell lung cancer (NSCLC) in Brunei Darussalam, and assesses …

Advances in First-and Second-Line Therapy of Small Cell Lung Cancer

SK Lu, P Giannatempo, M O'Brien - Emerging Cancer …, 2012 - books.google.com
Small cell lung cancer (SCLC) accounts for up to 20% to 25% of lung cancer. It is an aggressive
subtype and carries a poor prognosis. Over the past years, there have been numerous …